



PRESS RELEASE

FOR IMMEDIATE RELEASE

DNAVISION IS THE FIRST EUROPEAN SERVICE COMPANY TO PROVIDE CUSTOM SNP GENOTYPING USING LATEST TECHNOLOGY FROM AFFYMETRIX.

Brussels, June 23th 2006 – **DNAVision** announced today that its upgrade of one of their current GeneChip Systems with the new AFFYMETRIX GCS3000 Targeted Genotyping System. DNAVision is the **first full-service pharmacogenomic laboratory** to provide this custom genotyping solution in Europe.

Thanks to incorporation of MIP and Universal Tag technologies, the GeneChip Scanner 3000 Targeted Genotyping System addresses high-throughput SNPs screening challenges by offering flexible multiplexing from **1500 to 50000 SNPs per individual assay**.

“DNAVision is proud to be the **first European pharmacogenomic DNA testing laboratory** to provide this innovative tool. Genetic association studies are a powerful method for uncovering the basis of complex human disease and represent a valuable aspect of understand variability in response to therapeutics. By combining our high quality standards (**ISO17025 accredited, GLP compliant**) with this high-performing system, DNAVision will provide his customers with quality data given them the information they need to solve complete research programs” said Jean-Pol Detiffe, CEO of DNAVision SA.

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be

Further information:

Jean-Pol Detiffe
DNAVision SA
Tel. +32 71 378 527
Fax. +32 71 378 501
info@dnavision.be
www.dnavision.be